In its latest 10-Q filing for Q1 2026, NeoGenomics disclosed progress on integrating Pathline, an oncology diagnostics lab acquired in 2025, alongside test menu expansions and operational enhancements. The company’s CAP/CLIA/ISO-certified lab network across the U.S. and U.K. supports rapid turnaround molecular and cytogenetic testing focused on oncology. Despite regulatory challenges and competitive pressures, NeoGenomics leverages a consultative sales model and pharmaceutical partnerships to drive growth. Its financial profile shows adequate liquidity and manageable leverage supporting near-term investments.